West Pharmaceutical Services Inc's stock fell 3.36% and hit a 20-day low amid a broader market decline, with the Nasdaq-100 down 1.39% and the S&P 500 down 0.78%.
The company is set to announce its Q4 and full-year 2025 financial results on February 12, 2026, which is expected to impact investor confidence. Following the earnings release, a conference call will be held to discuss the results and business expectations, providing critical information for investors. In fiscal year 2024, West generated $2.89 billion in net sales, reinforcing its position as a leading provider of innovative injectable solutions.
The upcoming earnings report may influence market sentiment, especially given the current market conditions. Investors will be keen to assess the company's performance and outlook during the conference call.
Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 348.70 USD with a low forecast of 285.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 348.70 USD with a low forecast of 285.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 235.890
Low
285.00
Averages
348.70
High
375.00
Current: 235.890
Low
285.00
Averages
348.70
High
375.00
Nephron Research
Hold
to
Buy
upgrade
$367
2025-12-11
Reason
Nephron Research
Price Target
$367
AI Analysis
2025-12-11
upgrade
Hold
to
Buy
Reason
Nephron Research upgraded West Pharmaceutical to Buy from Hold with a $367 price target.
TD Cowen
Brendan Smith
Buy
initiated
$350
2025-10-29
Reason
TD Cowen
Brendan Smith
Price Target
$350
2025-10-29
initiated
Buy
Reason
TD Cowen analyst Brendan Smith initiated coverage of West Pharmaceutical with a Buy rating and $350 price target. West sits at the nexus of multiple, sector-wide trends - including injectable biologics, GLP-1s and expanding regulatory demand - that have helped the company evolve from a supplier of standard drug delivery components towards high-value products with higher gross margins, the analyst tells investors. The mix shift to higher value products should sustainably grow revenue and margins long term, the analyst contends.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for WST
Unlock Now
Barclays
Equal Weight
maintain
$275 -> $325
2025-10-27
Reason
Barclays
Price Target
$275 -> $325
2025-10-27
maintain
Equal Weight
Reason
Barclays raised the firm's price target on West Pharmaceutical to $325 from $275 and keeps an Equal Weight rating on the shares. The company reported a "solid beat across the board" and has a good setup into 2026, the analyst tells investors in a research note.
Evercore ISI
Daniel Markowitz
Tactical Outperform -> Outperform
downgrade
$390
2025-10-27
Reason
Evercore ISI
Daniel Markowitz
Price Target
$390
2025-10-27
downgrade
Tactical Outperform -> Outperform
Reason
Evercore ISI analyst Daniel Markowitz had a "Tactical Outperform" call on West Pharmaceutical heading into earnings, but is removing it from the firm's TAP list given that West reported earnings late last week. The firm has an Outperform rating and $390 price target on the shares.
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
